These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 11858936)

  • 1. PTEN: The down side of PI 3-kinase signalling.
    Leslie NR; Downes CP
    Cell Signal; 2002 Apr; 14(4):285-95. PubMed ID: 11858936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.
    Downes CP; Bennett D; McConnachie G; Leslie NR; Pass I; MacPhee C; Patel L; Gray A
    Biochem Soc Trans; 2001 Nov; 29(Pt 6):846-51. PubMed ID: 11709086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.
    Leslie NR; Bennett D; Gray A; Pass I; Hoang-Xuan K; Downes CP
    Biochem J; 2001 Jul; 357(Pt 2):427-35. PubMed ID: 11439092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors.
    Freeburn RW; Wright KL; Burgess SJ; Astoul E; Cantrell DA; Ward SG
    J Immunol; 2002 Nov; 169(10):5441-50. PubMed ID: 12421919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
    Leslie NR; Gray A; Pass I; Orchiston EA; Downes CP
    Biochem J; 2000 Mar; 346 Pt 3(Pt 3):827-33. PubMed ID: 10698713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute regulation of the tumour suppressor phosphatase, PTEN, by anionic lipids and reactive oxygen species.
    Downes CP; Walker S; McConnachie G; Lindsay Y; Batty IH; Leslie NR
    Biochem Soc Trans; 2004 Apr; 32(Pt 2):338-42. PubMed ID: 15046604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic switching of PI3K-dependent lipid signals.
    Downes CP; Leslie NR; Batty IH; van der Kaay J
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):188-92. PubMed ID: 17371235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of the PTEN phosphatase.
    Gericke A; Munson M; Ross AH
    Gene; 2006 Jun; 374():1-9. PubMed ID: 16675164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity.
    Meuillet EJ; Mahadevan D; Berggren M; Coon A; Powis G
    Arch Biochem Biophys; 2004 Sep; 429(2):123-33. PubMed ID: 15313215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway.
    Weng LP; Brown JL; Baker KM; Ostrowski MC; Eng C
    Hum Mol Genet; 2002 Jul; 11(15):1687-96. PubMed ID: 12095911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.
    Maehama T; Dixon JE
    J Biol Chem; 1998 May; 273(22):13375-8. PubMed ID: 9593664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles.
    Déléris P; Bacqueville D; Gayral S; Carrez L; Salles JP; Perret B; Breton-Douillon M
    J Biol Chem; 2003 Oct; 278(40):38884-91. PubMed ID: 12847108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.
    Raftopoulou M; Etienne-Manneville S; Self A; Nicholls S; Hall A
    Science; 2004 Feb; 303(5661):1179-81. PubMed ID: 14976311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.
    Steelman LS; Bertrand FE; McCubrey JA
    Expert Opin Ther Targets; 2004 Dec; 8(6):537-50. PubMed ID: 15584861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN: life as a tumor suppressor.
    Simpson L; Parsons R
    Exp Cell Res; 2001 Mar; 264(1):29-41. PubMed ID: 11237521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.
    Walker SM; Leslie NR; Perera NM; Batty IH; Downes CP
    Biochem J; 2004 Apr; 379(Pt 2):301-7. PubMed ID: 14711368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN and myotubularin: novel phosphoinositide phosphatases.
    Maehama T; Taylor GS; Dixon JE
    Annu Rev Biochem; 2001; 70():247-79. PubMed ID: 11395408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6-pentakisphosphate 3-phosphatase activity.
    Caffrey JJ; Darden T; Wenk MR; Shears SB
    FEBS Lett; 2001 Jun; 499(1-2):6-10. PubMed ID: 11418101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylinositol 3,4,5-trisphosphate modulation in SHIP2-deficient mouse embryonic fibroblasts.
    Blero D; Zhang J; Pesesse X; Payrastre B; Dumont JE; Schurmans S; Erneux C
    FEBS J; 2005 May; 272(10):2512-22. PubMed ID: 15885100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases.
    Backers K; Blero D; Paternotte N; Zhang J; Erneux C
    Adv Enzyme Regul; 2003; 43():15-28. PubMed ID: 12791379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.